| 前收盘价格 | 376.86 |
| 收盘价格 | 372.55 |
| 成交量 | 239,732 |
| 平均成交量 (3个月) | 354,958 |
| 市值 | 41,760,178,176 |
| 市盈率 (P/E TTM) | 66.16 |
| 预期市盈率 (P/E Forward) | 46.51 |
| 价格/销量 (P/S) | 6.76 |
| 股市价格/股市净资产 (P/B) | 7.85 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | -9.40% |
| 营业利益率 (TTM) | 0.99% |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 季度收入增长率 (YOY) | 48.60% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 1.96 |
| 营业现金流 (OCF TTM) | 212.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.68 M |
| 资产报酬率 (ROA TTM) | -3.22% |
| 股东权益报酬率 (ROE TTM) | -11.44% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | BeOne Medicines Ltd. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -5.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.88 |
|
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company’s main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 17.31% |
| 机构持股比例 | 43.94% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Capital International, Inc./Ca/ | 30 Jun 2026 | 305,477 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| OYLER JOHN | - | 359.11 | -240,810 | -86,472,679 |
| 累积净数量 | -240,810 | |||
| 累积净值 ($) | -86,472,679 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 359.11 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| OYLER JOHN | 职员 | 12 Aug 2026 | 自动卖出 (-) | 54,892 | 359.05 | 19,708,973 |
| OYLER JOHN | 职员 | 11 Aug 2026 | 自动卖出 (-) | 70,907 | 359.27 | 25,474,758 |
| OYLER JOHN | 职员 | 10 Aug 2026 | 自动卖出 (-) | 115,011 | 359.00 | 41,288,949 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合